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A single centre experience of four pregnancies in four cystic fibrosis (CF) lung transplant recipients is reported. Six more cases were
identified from the literature review and combined data analysis on 10 pregnancies in 10 CF lung transplant recipients was performed to
determine maternal, foetal and graft outcome. There were nine live births and one therapeutic abortion. Three required caesarean sections.
Five babies were premature but all nine children were well at follow-up. Five recipients who had a long, stable interval (i.e. at least three
years) between transplant and pregnancy had a favourable outcome. Three recipients developed rejection during the pregnancy and one
already had obliterative bronchiolitis before pregnancy. All showed progressive decline in lung function and subsequently died of chronic
rejection within 38 months of delivery. Pregnancy in CF lung transplant recipients is feasible but should still be regarded as a risky
undertaking.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pregnancy; Lung transplantation; Obliterative bronchiolitis; Rejection1. Introduction
Lung transplantation is now established as a therapeutic
option to prolong life in CF patients with end-stage lung
disease. The majority of CF female lung transplant recipients
are at their prime reproductive age. These patients can now
achieve five year survival of more than 50% and ten year
survival approaching 40% [1,2]. In view of prolonged
survival, improved quality of life and regaining of a near-
to-normal active life after transplantation, many of these
young women express a strong desire for pregnancy and
motherhood. Successful pregnancies following other solid
organ transplantation, i.e. kidney, liver and heart, have been
extensively reported [3,4]. These reports show that there is no
significant increased risk of congenital malformation or
neonatal infection related to long-term immunosuppressive
drugs. Only limited cases of pregnancy following lung1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.03.001
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E-mail address: k.gyi@rbht.nhs.uk (K.M. Gyi).transplantation for different end-stage lung disease have
been described [4–10]. These reports have shown variable
outcomes of foetal, maternal and graft function.
This review focused on pregnancy in CF lung transplant
recipients and should help CF patients to make an informed
decision about pregnancy and also guide the physicians in
their management of these patients.2. Methods
Between 1985 and 2003 four CF lung transplant
recipients who had been pregnant were identified at the
Royal Brompton and Harefield transplant centre. Data was
recorded from hospital records (CF notes, transplant notes,
obstetric notes and correspondence). Some information and
up to date data on the children were obtained by telephone
interview after verbal consent. All published reports on the
pregnancy in lung transplant recipients were first collected
from a Medline search using Fpregnancy in/after/following5 (2006) 171 – 175ed by Elsevier B.V. All rights reserved.
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Fig. 1. % predicted FEV1 before, during and post-pregnancy.
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nancies in six CF lung transplant recipients were identified
[6–8]. Together with four patients described below,
combined data analysis on 10 pregnancies in 10 CF lung
transplant recipients was performed to assess overall
maternal, graft and foetal outcome and to identify any
factor which may predict the outcome of the pregnancy.3. Case reports (Fig. 1; Tables 1 and 2)
3.1. Case 1
This patient (previously reported in Ref. [4]) was
diagnosed with CF at birth. She was pancreatic insufficient
and had no history of diabetes. Her airway was colonised
with Pseudomonas aeruginosa. She underwent heart– lung
transplant at the age of 26 years. Her maintenance
immunosuppression was azathioprine and cyclosporin. She
was treated twice for acute rejection within six months of
transplant. Her lung function was stable with an FEV1 of
91% predicted when she became pregnant at 30 months
post-transplant. Her cyclosporin dose was increased. At 12
weeks her lung function dropped and she was empirically
treated with a steroid pulse. Lung function further declined
and at 24 weeks gestation obliterative bronchiolitis (OB)Table 1
Maternal and graft characteristics before, during, after pregnancy and ultimate re
Pts no. Age
(yrs)
Interval*
(yrs)
Type of
transplant
Rejection before
pregnancy
1 28 2.5 HLT AR2
2 30 4.75 HLT No
3 28 2.75 BSL AR2, OB
4 22 3.25 HLT No
5 30 1.1 LOBE AR1
6 32 3.3 DL AR1
7 26 1.1 BSL AR3
8 22 1.2 BSL No
9 26 >3 HLT NA
10 26 >3 HLT NA
HLT — heart lung transplant; LOBE — living lobe transplant; BSL — bilateral si
OB — obliterative bronchiolitis; CSA — Cyclosporin A; NA — information notwas diagnosed histologically, and she was treated with
further steroid pulse. She also developed hypertension. She
underwent semi-elective caesarean section at 32 weeks
gestation and delivered a female baby. Her OB became
progressive and underwent single lung re-transplantation at
six months but subsequently died of OB and recurrent chest
infections at 25 months post-delivery. The child is well at 10
years (Fig. 1; Tables 1 and 2).
3.2. Case 2
This patient was diagnosed with CF at birth. She was
pancreatic sufficient with no history of diabetes, and her
airway was colonised with P. aeruginosa. She underwent
heart–lung transplant at the age of 25 years. She had no
acute rejection during the post-transplant period. Her
maintenance immunosuppression was azathioprine and
cyclosporin. Her pulmonary function was stable with a
FEV1 of 78% predicted when she became pregnant at 57
months post-transplant. The cyclosporin dose was in-
creased. During the third trimester, her lung function
dropped and she was treated for Staphylococcus aureus
and P. aeruginosa chest infection and was also given one
empirical methyl prednisolone pulse. She responded to
treatment and her lung function returned to base line.
Following induction at 34 weeks gestation, she had a
successful vaginal delivery of a female baby. Her pulmonary
function remained stable at pre-pregnancy levels until 30
months post-delivery when her lung function dropped and a
CT scan showed mild bronchiectasis and air trapping.
Bronchial biopsy was negative. She was treated with a
steroid pulse and the cyclosporin changed to tacrolimus. Her
lung function became stable at FEV1 71% predicted. The
child is now 6.5 years old and well.
3.3. Case 3
This patient was diagnosed CF at birth. She was
pancreatic insufficient. Her airway was colonised with P.cipient outcome
Rejection during
pregnancy
Rejection after pregnancy
and ultimate recipient outcome
after delivery
OB Died of OB at 19/12
No Lung function adequate at 6 years
OB Died of OB at 38/12
Rejection Lung function adequate at 2 years
No Lung function adequate at 16/12
No AR1. Lung function adequate at 15/12
OB Died of OB at 30/12 post-termination
AR1 Died of OB at 18/12
No Lung function stable at 3 years
No Lung function stable at 3 years
ngle lung transplant; DL — double lung transplant; AR — Acute rejection;
available, *Interval = transplant to conception interval in years.
Table 2
Newborn and child outcome
No. Premature <37 weeks Mode of delivery Birth weight (g) Complication in newborn Ultimate child outcome
1 Yes (32) CS 1588 No Well at 10 years
2 Yes (34) NSVD 2460 No Well at 6.5 years
3 No (37) CS 2438 No Well at 3 years
4 No (39) NSVD 3005 No Well at 2 years
5 Yes (31.5) NSVD 2665 Yes Well at 1.3 years
6 Yes (30) CS 1616 Yes Well at 1.3 years
7 TA (16) TA
8 Yes (30) NSVD 1077 Yes Well at 1.6 years
9 No (37) NSVD a No Well at 3 years
10 No (37) NSVD a No Well at 3 years
CS — caesarean section; NSVD — normal spontaneous vaginal delivery; TA — therapeutic abortion.
a Mean birth weight 3143T757 g (as stated in Ref. [7]).
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age of 25 years and was treated twice for acute rejection
immediately after transplant. Her maintenance immunosup-
pression was cyclosporin, azathioprine and steroids. At 10
months post-transplant her lung function dropped due to
histologically diagnosed OB. This was treated with steroid
pulse and the cyclosporin was changed to tacrolimus. She
then developed diabetes mellitus requiring insulin. Her lung
function continued to decline and she therefore underwent
total lymphoid irradiation (TLI). She had ovariopexy done
before her TLI to protect the ovaries. Following the TLI her
lung function became stable with an FEV1 of around 48%
predicted. As she was feeling well and her lung function
was stable, she discussed her strong desire for pregnancy. In
view of OB, previous treatment with TLI, limited lung
function (FEV1 48%) and insulin dependent diabetes
mellitus, she was strongly advised against pregnancy.
However, she insisted and became pregnant at 33 months
after her transplant. Her tacrolimus dose was increased and
her lung function was stable throughout the pregnancy. At
37 weeks gestation she underwent emergency caesarean
section for slight anti-partum haemorrhage and increased
foetal heart rate and delivered a healthy female baby. Her
lung function remained stable at her pre-pregnant level for
the first two years then declined due to progressive OB. She
subsequently died of recurrent chest infections and OB at 38
months post-delivery. The child is well at three years old.
3.4. Case 4
Patient 4 underwent heart–lung transplant aged 19 years.
She was diagnosed CF at birth. She was pancreatic
insufficient and was colonised with P. aeruginosa. She
had no acute rejection post-transplant. Her immunosuppres-
sion was maintained with cyclosporin, azathioprine and
prednisolone. She achieved a FEV1 of 138% predicted and
became pregnant at 39 months post-transplant. Her cyclo-
sporin level was frequently below the therapeutic level
throughout the pregnancy. Her lung function dropped during
the third trimester and she was treated for a chest infection.
She had a spontaneous vaginal delivery of a female baby at39 weeks gestation. Her lung function remained reduced
post-partum. Bronchial biopsy was negative and bronchial
lavage grew Stenotrophomonas maltophilia. A CT scan of
the thorax showed bronchiectasis, airway dilatation and air
trapping. Her immunosuppression was changed to tacroli-
mus, mycophenolate and prednisolone. She was also given
inhaled colistin. Her FEV1 slightly improved and remained
stable at 90% predicted. The child is well at two years.4. Literature review
Limited cases of pregnancy following lung transplanta-
tion for different types of end-stage lung diseases have been
reported [4]. There were reports on six pregnancies in six
CF patients [6–8]. Gartner and Armeti described four cases
(cases 5–8). Baron’s paper on pregnancy in HLT included
two CF patients (cases 9,10) but not all details were
available [8]. We added our four cases described above
(cases 1–4) and carried out combined analysis on 10 CF
pregnancies in 10 CF patients.
4.1. Maternal outcome (Table 1)
Median maternal age was 27 (range 22–32) years. Two
developed hypertension but there were no reports of
eclampsia or toxaemia. Two had diabetes before pregnancy
and one case developed glucose intolerance during high
dose steroid treatment. Three developed chest infection
during pregnancy but all were successfully treated with
antibiotics. Three (33%) required caesarean section. Patient
6 went into pre-term labour at 24 weeks but settled after bed
rest. Maternal follow-up after delivery ranged from 18 to 72
months. Four (40%) maternal deaths occurred after a mean
survival of 26 months post-partum.
4.2. Graft function before, during and after pregnancy and
ultimate recipient outcome (Table 1)
Information on graft function before pregnancy was
available on 8 patients (cases 1 to 8). Five had experienced
K.M. Gyi et al. / Journal of Cystic Fibrosis 5 (2006) 171–175174acute rejection (AR) before they became pregnant. Three
cases (cases 1,3,7) who had more than one acute rejection
episode developed chronic rejection (obliterative bronchio-
litis) during the pregnancy and subsequently died. Case 7
who had three episodes of rejection, the most recent being
five months before conception became pregnant 13 months
after transplant. She developed OB during the first
trimester which was complicated by deep vein thrombosis
and respiratory distress. She underwent termination of
pregnancy and died of OB 30 months later despite re-
transplantation.
Five patients had rejection (either acute rejection or OB)
during pregnancy. Four cases (cases 1,4,7,8) had a new
onset rejection and patient 3 already had OB before
pregnancy. All cases except case 4 developed progressive
OB after delivery and died within 38 months. In case 4, low
level of cyclosporin throughout the pregnancy may have
contributed to her rejection and when immunosuppression
was augmented her lung function stabilised. Immunosup-
pression requirement can increase during pregnancy due to
increased volume of distribution and increased metabolism
[10]. All patients had a fall in immunosuppression level
after the first trimester and needed dose adjustment.
From experience with other solid organs a stable period
of 15 to 24 months is recommended between transplant and
pregnancy [3]. The interval between transplant and concep-
tion in this series ranged from 1.1 to 4.75 years with mean
of 2.4 years. Apart from case 4, all patients who became
pregnant more than 3 years after transplant (cases 2,6,9,10)
developed no rejection and maintained stable lung function
throughout the pregnancy. Case 5, who had a living donor
lobar transplant, became pregnant at 1.1 years and had a
good outcome. This could be related to the type of
transplant, as a low incidence of OB has been reported in
patients with living lobe transplants [11].
4.3. Neonatal and child outcome (Table 2)
As reported in other solid organ transplant pregnancies,
CF lung transplant pregnancy is associated with a higher
rate of prematurity and low birth weight than normal
[3,4,10]. The premature rate is usually higher even in non-
transplant CF female patients with poor lung function and
malnutrition [12]. The causes of prematurity and low birth
weight are multifactorial and may include malabsorption,
hypertension, immunosuppressive drugs, maternal infection
and rejection. Five out of nine live births (56%) were
premature. Low birth weight (<2500 g) occurred in five
(56%) of newborn babies. Two newborn babies required
ventilatory assistance and one developed necrotising en-
terocolitis and adrenal suppression (cases 5,7,8). All three
recovered completely. There were no reports of congenital
malformation or long-term medical problems. All nine
children were reported to be well at follow-up, ranging
from 1.6 to 10 years. Three children lost their mothers
before their fourth birthday.5. Discussion
Most experience of outcome after pregnancy in solid
organ transplant comes from renal transplantation [3,4,13].
Generally pregnancy does not appear to have a negative
impact on renal graft if the graft function has been stable
before the pregnancy. The risk of prematurity and low birth
weight are reported to be over 50% [4,13]. There is no
significant increased incidence or any pattern of congenital
malformation associated with commonly used immunosup-
pression, i.e. cyclosporin, tacrolimus, azathioprine and
steroids [14]. In our series incidence of prematurity and
low birth weight was equally high at 56%.
Compared to other solid organ transplants lung trans-
plant recipients experience more frequent rejection during
pregnancy, and graft loss post-partum. Our data compared
to renal transplant data showed a higher rejection rate of
40% versus 4%, and graft loss within 2 years of 30%
versus 13% [4].
Many CF potential lung transplant candidates ask if, after
their transplant when normal health is restored, it would be
possible for them to undergo pregnancy. Some CF females
may have reduced fertility due to thick cervical mucus and
disturbed ovulation. However, fertility is usually normal in
the majority of healthy female CF patients [12]. It is
therefore important that appropriate contraceptive advice is
given to all CF female lung transplant recipients to avoid an
unplanned pregnancy.
CF transplant recipients who want to undergo pregnancy,
and the partner, should be counselled before conception, and
the potential risk to mother, graft and child should be frankly
discussed. They must be informed about the unpredictability
of graft dysfunction, which can occur at anytime during
pregnancy, and may be followed by progressive decline and
eventual death after delivery. The couple should be aware that
the mother may not have a chance to see the child grow up.
They should be explained about the potential risk of some
investigations e.g. bronchoscopy and radiological examina-
tion, and the potential teratogenic effect of some drugs which
may be used if recipients develop complications during
pregnancy. Potential parents should be made aware of the
possibility of having premature infants whomay survive with
disability. They also need to know the heavy burden made by
a healthy or disabled infant on a mother with declining health.
Despite the prematurity rate of 56% and the neonatal
complication rate of 33%, the data so far showed no long-
term morbidity in the children. This should be interpreted
with caution because of the retrospective nature of the study,
small number of patients and short period of follow-up.
If the CF transplant recipients insist on pregnancy this
should be planned. Carrier screening for the partner is
advised to estimate the risk of CF in the child and appropriate
genetic counselling is given. Although numbers are small it
appears that transplant to conception interval and number of
rejection episodes before the pregnancy may play a role in
predicting the outcome of pregnancy. Increased frequency
K.M. Gyi et al. / Journal of Cystic Fibrosis 5 (2006) 171–175 175and severity of acute rejections are known risk factors for
development of chronic rejection [16]. In this series
recipients with no or minimal rejection (<2) who became
pregnant after interval of at least 3 years or more generally
had a favourable maternal and graft outcome. Therefore it is
advisable for CF transplant recipients to wait for a stable
interval of at least three years before considering pregnancy.
Recipients with a history of frequent early rejections or who
have already developed chronic rejection with limited lung
function should be warned about the potential increased risk
and strongly advised against pregnancy. CF pregnancy with
FEV1 <50% predicted is usually associated with a poor
outcome [15].
The pregnancy should be jointly followed by the
transplant and obstetric team at least monthly and fortnightly
during the third trimester. A CF physician’s input should be
available at the request of the transplant team. Screening for
diabetes is carried out and insulin treatment given if present.
Nutrition is optimised and the blood pressure should be well
controlled. The dose of immunosuppressive drugs should be
monitored closely i.e. at least monthly, and the dose adjusted
accordingly to keep to the target maintenance level.
Recipients should monitor their spirometry daily and report
to the transplant team if there is a persistent drop. Prompt
treatment is given for rejection and infection. Delivery is
carefully planned by discussion between transplant and
obstetric teams depending on maternal, graft and foetal
condition. Close monitoring of lung function and immuno-
suppressive drug level is continued after delivery to detect
any graft dysfunction as a result of rebound immunity
phenomenon [17].
Current evidence suggests a few CF lung transplant
recipients can achieve a successful outcome if their
pregnancy is preceded by a prolonged period of stable graft
function with no or minimal rejection. Graft rejection and
graft function loss are unpredictable and can occur with
grave consequences to the mother. Case numbers are still
too small to predict the outcome confidently for an
individual patient. It should still be regarded as a highly
risky undertaking. Further studies in a large number of lung
transplant recipients from different transplant centres are
necessary to determine whether long-term maternal survival
is affected by pregnancy.References
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